2024-06-29
04:15 |
|
17 p, 21.8 MB |
Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide
/
Serrano, Guillermo (Universidad de Navarra) ;
Berastegui, Nerea (Universidad de Navarra) ;
Díaz-Mazkiaran, Aintzane (Universidad de Navarra) ;
García-Olloqui, Paula (Universidad de Navarra) ;
Rodriguez-Res, Carmen (Universidad de Navarra) ;
Huerga-Dominguez, Sofia (Universidad de Navarra) ;
Ainciburu, Marina (Universidad de Navarra) ;
Vilas-Zornoza, Amaia (Universidad de Navarra) ;
Martin-Uriz, Patxi San (Universidad de Navarra) ;
Aguirre-Ruiz, Paula (Universidad de Navarra) ;
Ullate-Agote, Asier (Universidad de Navarra A) ;
Ariceta, Beñat (Universidad de Navarra) ;
Lamo-Espinosa, Jose-Maria (Universidad de Navarra) ;
Acha, Pamela (Vall d'Hebron Institut d'Oncologia) ;
Calvete, Oriol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Jimenez, Tamara (Hospital Universitario de Salamanca-IBSAL. Department of Hematology) ;
Molero, Antonieta (Vall d'Hebron Institut d'Oncologia) ;
Montoro, Maria Julia (Vall d'Hebron Institut d'Oncologia) ;
Diez-Campelo, María (Hospital Universitario de Salamanca) ;
Valcárcel, David (Vall d'Hebron Institut d'Oncologia) ;
Sole, F (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Alfonso-Piérola, Ana (Universidad de Navarra) ;
Ochoa, Idoia (Universidad de Navarra) ;
Prosper, Felipe (Universidad de Navarra) ;
Ezponda, Teresa (Universidad de Navarra) ;
Hernaez, Mikel (Universidad de Navarra) ;
Universitat Autònoma de Barcelona
While myelodysplastic syndromes with del(5q) (del(5q) MDS) comprises a well-defined hematological subgroup, the molecular basis underlying its origin remains unknown. Using single cell RNA-seq (scRNA-seq) on CD34 + progenitors from del(5q) MDS patients, we have identified cells harboring the deletion, characterizing the transcriptional impact of this genetic insult on disease pathogenesis and treatment response. [...]
2024 -  10.1038/s41467-024-49529-x
Nature communications, Vol. 15 (june 2024)
|
|
2024-06-25
09:54 |
|
11 p, 2.6 MB |
CXCR4 Expression as a Prognostic Biomarker in Soft Tissue Sarcomas
/
Virgili Manrique, Anna Cristina (Institut de Recerca Sant Pau) ;
Salazar, Juliana (Institut de Recerca Sant Pau) ;
Gallardo, Alberto (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
López Pousa, Antonio (Institut de Recerca Sant Pau) ;
Terés, Raúl (Institut de Recerca Sant Pau) ;
Bagué Rosell, Sílvia (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Orellana-Fernández, Ruth (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Fumagalli, Caterina (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Mangues, Ramon 1957- (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Alba-Castellón, Lorena (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Unzueta Elorza, Ugutz (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Casanova Rigat, Isolda (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sebio, Ana (Institut de Recerca Sant Pau) ;
Universitat Autònoma de Barcelona
Poor long-term survival in localized high-risk soft tissue sarcomas (STSs) of the extremities and trunk highlights the need to identify new prognostic factors. CXCR4 is a chemokine receptor involved in tumor progression, angiogenesis, and metastasis. [...]
2024 - 10.3390/diagnostics14111195
Diagnostics, Vol. 14 Núm. 11 (june 2024) , p. 1195
|
|
2024-06-20
04:50 |
|
14 p, 3.2 MB |
SIRT7 and p53 interaction in embryonic development and tumorigenesis
/
Vazquez Prat, Berta Nieves (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Fernández-Duran, Irene (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Hernandez, Yurdiana (Rutgers University (Piscataway, Estats Units d'Amèrica)) ;
Tarighi, Shahriar (Max-Planck-Institute for Heart and Lung Research. Department of Cardiac Development and Remodeling) ;
Thackray, Joshua K. (Rutgers University (Piscataway, Estats Units d'Amèrica)) ;
Espinosa-Alcantud, Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Kumari, Poonam (Max-Planck-Institute for Heart and Lung Research. Department of Cardiac Development and Remodeling) ;
Ianni, Alessandro (Max-Planck-Institute for Heart and Lung Research. Department of Cardiac Development and Remodeling) ;
Cesaire, Lionel (The City University of New York. Department of Science) ;
Braun, Thomas (Max-Planck-Institute for Heart and Lung Research. Department of Cardiac Development and Remodeling) ;
Esteller, M (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Tischfield, Jay (Rutgers University (Piscataway, Estats Units d'Amèrica)) ;
Vaquero, Alejandro (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Serrano, Lourdes (The City University of New York. Department of Science)
p53 is a hallmark tumor suppressor due in part to its role in cell cycle progression, DNA damage repair, and cellular apoptosis; its protein activity interrelates with the Sirtuin family of proteins, major regulators of the cellular response to metabolic, oxidative, and genotoxic stress. [...]
2024 - 10.3389/fcell.2023.1281730
Frontiers in Cell and Developmental Biology, Vol. 11 (january 2024)
|
|
2024-06-20
04:50 |
|
14 p, 1.9 MB |
The C250T Mutation of TERTp Might Grant a Better Prognosis to Glioblastoma by Exerting Less Biological Effect on Telomeres and Chromosomes Than the C228T Mutation
/
Gorria, Teresa (Hospital Clínic i Provincial de Barcelona) ;
Crous, Carme (Hospital Clínic) ;
Pineda, Estela (Hospital Clínic i Provincial de Barcelona) ;
Hernandez, Ainhoa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Domènech Viñolas, Marta (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Sanz, Carolina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Jares, Pedro (Hospital Clínic i Provincial de Barcelona) ;
Muñoz-Mármol, Ana María (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Arpí-Llucía, Oriol (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Melendez, Bárbara (Hospital Universitario de Toledo (Toledo, Castella-La Mantxa)) ;
Gut, Marta (Centro Nacional de Análisis Genómico (Barcelona)) ;
Esteve, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Esteve-Codina, Anna (Centro Nacional de Análisis Genómico (Barcelona)) ;
Parra, Genis (Centro Nacional de Análisis Genómico (Barcelona)) ;
Alameda, Francesc (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Carrato, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Aldecoa, Iban (Hospital Clínic i Provincial de Barcelona) ;
Mallo, Maria del Mar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
de la Iglesia, Nuria (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Balana, Carmen (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Universitat Autònoma de Barcelona
In our glioblastoma patients treated with standard therapy, the TERTp C250T mutation occurred less frequently than the C228T mutation. Patients with the C250T mutation had better prognosis than those with either TERTp -wt or TERTp C228T mutations, even when adjusted for key glioblastoma prognostic factors. [...]
2024 - 10.3390/cancers16040735
Cancers, Vol. 16 (february 2024)
|
|
2024-04-09
04:01 |
|
18 p, 2.0 MB |
Persistence of Chronic Lymphocytic Leukemia Stem-like Populations under Simultaneous In Vitro Treatment with Curcumin, Fludarabine, and Ibrutinib : Implications for Therapy Resistance
/
Bistué Rovira, Àngel (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
G. Rico, Laura (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Bardina, Jorge (Vall d'Hebron Institut d'Oncologia) ;
Junca, Jordi (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Granada, Isabel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bradford, Jolene A. (Thermo Fisher Scientific (Estats Units d'Amèrica)) ;
Ward, Michael D. (Thermo Fisher Scientific (Estats Units d'Amèrica)) ;
Salvia, Roser (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Sole, F (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Petriz, Jordi (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Leukemic stem cells (LSCs) possess similar characteristics to normal hematopoietic stem cells, including self-renewal capacity, quiescence, ability to initiate leukemia, and drug resistance. These cells play a significant role in leukemia relapse, persisting even after apparent remission. [...]
2024 - 10.3390/ijms25041994
International journal of molecular sciences, Vol. 25, Num. 4 (february 2024)
|
|
2024-03-14
05:34 |
|
9 p, 3.8 MB |
Zinc-Assisted Microscale Granules Made of the SARS-CoV-2 Spike Protein Trigger Neutralizing, Antivirus Antibody Responses
/
de Pinho Favaro, Marianna T (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Álamo, Patricia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Roher Armentia, Nerea (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Chillón Rodríguez, Miguel (Universitat Autònoma de Barcelona. Institut de Neurociències) ;
Lascorz Lozano, Jara A (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Márquez, Merce (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Corchero Nieto, José Luis (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Mendoza, Rosa (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Martínez-Torró, Carlos (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Ferrer-Miralles, Neus (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ;
Ferreira, Luis (Universidade de São Paulo) ;
Mangues, Ramon 1957- (Institut d'Investigació Biomèdica Sant Pau) ;
Vázquez Gómez, Esther (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ;
Parladé Molist, Eloi (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Villaverde Corrales, Antonio (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Universitat Autònoma de Barcelona.
SGR - Bio-fàrmacs innovadors
The development of new and more efficient vaccination approaches is a constant need, due to the pressure of historical and emerging infectious diseases and the limited efficacy and universality of the current vaccination technologies. [...]
2024 - 10.1021/acsmaterialslett.3c01643
ACS materials letters, Vol. 6, Issue 3 (February 2024) , p. 954-962
|
|
2024-03-07
17:25 |
|
6 p, 1.1 MB |
Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab : part 3 of the open-label, multicenter, phase 1b PAVO study
/
Nahi, Hareth (Karolinska Institute. Department of Medicine) ;
Usmani, Saad Z. (Memorial Sloan Kettering Cancer Center) ;
Mateos, M. V (Hospital Universitario de Salamanca) ;
van de Donk, Niels W C J (Department of Hematology. Vrije Universiteit Amsterdam) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Plesner, Torben (Vejle Hospital and University of Southern Denmark) ;
Bandyopadhyay, Nibedita (Janssen Research & Development. LLC) ;
Hellemans, Peter (Janssen Research & Development) ;
Tromp, Brenda (Janssen Research & Development. LLC) ;
Nnane, Ivo (Janssen Research & Development. LLC) ;
Zemlickis, Donna (Janssen Research & Development. LLC) ;
Chari, Ajai (Icahn School of Medicine at Mount Sinai) ;
Moreau, Philippe (University Hospital Hôtel-Dieu (Nantes, França))
2023 - 10.1080/10428194.2022.2148221
Leukemia and Lymphoma, Vol. 64 Núm. 2 (2023) , p. 468-472
|
|
2024-03-07
17:25 |
|
18 p, 1.8 MB |
Serum DNA methylome of the colorectal cancer serrated pathway enables non-invasive detection
/
Gallardo-Gómez, María (Universidade de Vigo) ;
Costas-Ríos, Lara (Universidade de Vigo) ;
García-Prieto, Carlos A (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Álvarez-Rodríguez, Lara (Universidade de Vigo) ;
Bujanda, Luis (Universidad del País Vasco) ;
Barrero, Maialen (Hospital de Donostia (Sant Sebastià, País Basc)) ;
Castells, Antoni (Hospital Clínic i Provincial de Barcelona) ;
Balaguer, Francesc (Hospital Clínic i Provincial de Barcelona) ;
Jover, Rodrigo (Universidad Miguel Hernández, Alicante) ;
Esteller, M (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Tardío Baiges, Antoni (Instituto de Investigación Biomédica Galicia Sur) ;
González-Carreró Fojón, Joaquín (Instituto de Investigación Biomédica Galicia Sur) ;
Cubiella, Joaquín (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Ourense) ;
De Chiara, Loretta (Universidade de Vigo)
The clinical relevance of the colorectal cancer serrated pathway is evident, but the screening of serrated lesions remains challenging. We aimed to characterize the serum methylome of the serrated pathway and to evaluate circulating cell-free DNA (cfDNA) methylomes as a potential source of biomarkers for the non-invasive detection of serrated lesions. [...]
2023 - 10.1002/1878-0261.13573
Molecular Oncology, 2023
|
|
2024-03-07
17:25 |
|
16 p, 3.7 MB |
An epigenetic switch controls an alternative NR2F2 isoform that unleashes a metastatic program in melanoma
/
Davalos, Veronica (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Lovell, Claudia D. (New York University School of Medicine, USA) ;
Von Itter, Richard (New York University School of Medicine, USA) ;
Dolgalev, Igor (New York University Grossman School of Medicine, USA) ;
Agrawal, Praveen (New York University Grossman School of Medicine, USA) ;
Baptiste, Gillian (New York University Grossman School of Medicine, USA) ;
Kahler, David J. (New York University Grossman School of Medicine, USA) ;
Sokolova, Elena (New York University Grossman School of Medicine, USA) ;
Moran, S (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Piqué, Laia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Vega-Saenz de Miera, Eleazar (New York University School of Medicine, USA) ;
Fontanals-Cirera, Barbara (New York University School of Medicine, USA) ;
Karz, Alcida (New York University School of Medicine, USA) ;
Tsirigos, Aristotelis (New York University Grossman School of Medicine, USA) ;
Yun, Chi (New York University Grossman School of Medicine, USA) ;
Darvishian, Farbod (New York University Grossman School of Medicine, USA) ;
Etchevers, Heather C. (Aix-Marseille University, Marseille, France) ;
Osman, Iman (New York University Grossman School of Medicine, USA) ;
Esteller, M (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Schober, Markus (New York University School of Medicine, USA) ;
Hernando, Eva (New York University Grossman School of Medicine, USA)
Metastatic melanoma develops once transformed melanocytic cells begin to de-differentiate into migratory and invasive melanoma cells with neural crest cell (NCC)-like and epithelial-to-mesenchymal transition (EMT)-like features. [...]
2023 - 10.1038/s41467-023-36967-2
Nature communications, Vol. 14 Núm. 1 (april 2023)
|
|
2024-03-07
17:25 |
|
11 p, 618.2 KB |
Characterization of the endotheliopathy, innate-immune activation and hemostatic imbalance underlying CAR-T cell toxicities : Laboratory tools for an early and differential diagnosis
/
Moreno-Castaño, Ana Belén (Hospital Clínic i Provincial de Barcelona) ;
Fernández, Sara (Hospital Clínic i Provincial de Barcelona) ;
Ventosa, Helena (Hospital Clínic i Provincial de Barcelona) ;
Palomo, Marta (Hospital Clínic i Provincial de Barcelona) ;
Martinez-Sanchez, Julia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ramos, Alex (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ortiz-Maldonado, Valentín (Hospital Clínic i Provincial de Barcelona) ;
Delgado, Julio (Hospital Clínic i Provincial de Barcelona) ;
Fernández De Larrea, Carlos (Hospital Clínic i Provincial de Barcelona) ;
Urbano Ispizua, Álvaro (Hospital Clínic i Provincial de Barcelona) ;
Penack, Olaf (Charité - Universitätsmedizin Berlin) ;
Nicolás, J.M. (Hospital Clínic i Provincial de Barcelona) ;
Téllez, Adrian (Hospital Clínic i Provincial de Barcelona) ;
Escolar, Ginès (Hospital Clínic i Provincial de Barcelona) ;
Carreras, Enric (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Fernández-Avilés, Francesc (Hospital Clínic i Provincial de Barcelona) ;
Castro Rebollo, Pedro (Hospital Clínic i Provincial de Barcelona) ;
Diaz-Ricart, Maribel (Hospital Clínic i Provincial de Barcelona)
Background Chimeric antigen receptor (CAR)-T cell-based immunotherapy constitutes a revolutionary advance for treatment of relapsed/refractory hematological malignancies. Nevertheless, cytokine release and immune effector cell-associated neurotoxicity syndromes are life-threatening toxicities in which the endothelium could be a pathophysiological substrate. [...]
2023 - 10.1136/jitc-2022-006365
Journal for immunotherapy of cancer, Vol. 11 Núm. 4 (april 2023)
|
|
|
|
visitante ::
identificación
Estadísticas de uso
Los más consultados
